John M Robbins

US Patent:

6607725, Aug 19, 2003

Filed:

Feb 20, 2001

Appl. No.:

09/789017

Inventors:

Chao-Ming Tsai - Bethesda MD
David J. Lim - Pasadena CA
John B. Robbins - Chevy Chase MD

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 39395

US Classification:

4241841, 4241781, 4241831, 4241931, 4242011, 4242021, 4242031, 4242341, 4242561, 4242701, 435 693, 435183, 435271, 435274, 435851

Abstract:

A conjugate vaccine for Nontypeable comprising lipooligosaccharide from which esterified fatty acids have been removed conjugated to an immunogenic carrier. The vaccine is useful for prevention of otitis media and respiratory infections in mammals.

US Patent:

6632437, Oct 14, 2003

Filed:

Nov 15, 1993

Appl. No.:

08/153263

Inventors:

Rachel Schneerson - Bethesda MD
John B. Robbins - Chevy Chase MD
J. N. Sarvamangala Devi - Columbia MD

Assignee:

The United States of America as represented by the Department of Health and Human Services - DC

International Classification:

A61K 39385

US Classification:

4241931, 4241371, 4241941, 42419711, 4242411, 530403, 530404, 530405, 530406

Abstract:

The present invention relates to a polysaccharide-protein conjugate. The invention also relates to a method of using the conjugate to prevent systemic infections. The invention further relates to a pharmaceutical composition. The invention also relates to a method of producing a polysaccharide-protein conjugate.

US Patent:

6685949, Feb 3, 2004

Filed:

Jul 5, 2000

Appl. No.:

09/610034

Inventors:

John B. Robbins - Chevy Chase MD

Assignee:

The United States of America as represented by the Department of Health Human Services - Washington DC

International Classification:

A61K 3902

US Classification:

4242511, 42419711, 424 92, 4241841, 4242341, 435 72, 435 97, 435170, 435197

Abstract:

A conjugate vaccine for ( ) comprising isolated lipooligosaccharide from which esterified fatty acids have been removed, to produce a detoxified lipooligosaccharide (dLOS), or from which lipid A has been removed, to produce a detoxified oligosaccharide (OS), which is linked to an immunogenic carrier. The vaccine is useful for preventing otitis media and respiratory infections caused by in mammals, including humans.

US Patent:

6797275, Sep 28, 2004

Filed:

Sep 1, 2000

Appl. No.:

09/653433

Inventors:

Zuzana Kossaczka - Bethesda MD
Shousun Chen Szu - Bethesda MD
John B. Robbins - Chevy Chase MD

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 39112

US Classification:

4242581, 42419511, 4241841, 4241971, 4242361, 4241921, 536123, 528332

Abstract:

This invention relates to conjugates of the Vi polysaccharide of with the carrier recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies againt and are useful to prevent and/or treat illnesses caused by.

US Patent:

6858211, Feb 22, 2005

Filed:

Jul 20, 1998

Appl. No.:

09/744289

Inventors:

Shousun Chen Szu - Bethesda MD, US
John B. Robbins - Chevy Chase MD, US
Yvonne Ageyman Konadu - Bronx NY, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K039/385

US Classification:

4241931, 4242581, 4242511, 4241841, 42419711, 42423411, 424 92, 4241921, 42419511, 4242361, 424725, 4242401, 4242441, 530403, 530404, 530405, 530406

Abstract:

This invention relates to conjugates of the O-specific polysaccharide of O157 with a carrier, and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (→3)-α-D-GalpNAc-(1→2)-α-D-PerpNAc-(1→3)-α-L-Fucp-(1→4)-β-D-Glcp-(1→), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing in particular O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against against in particular O157, and are useful to prevent and/or treat illnesses caused by O157. The invention further relates to the antibodies which immunoreact with the O-specific polysaccharide of O157 and/or the carrier, that are induced by these conjugates and/or compositions thereof. The invention also relates to methods and kits using one or more of the polysaccharides, conjugates or antibodies described above.

US Patent:

7247307, Jul 24, 2007

Filed:

Dec 16, 2004

Appl. No.:

11/015436

Inventors:

Shousun Chen Szu - Bethesda MD, US
John B. Robbins - Chevy Chase MD, US
Edward Konadu, deceased - Ashanti Region, GH

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/108
A61K 39/385

US Classification:

4242411, 4242341, 4242031, 42419711, 4241931

Abstract:

This invention relates to conjugates of the O-specific polysaccharide of O157 with a carrier, and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (→3)-α-DGalpNAc-(1→2)-α-D-PerpNAc-(1→3)-α-L-Fucp-(1→4)-β-D-Glcp-(1→), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing , in particular O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against , in particular O157, and are useful to prevent and/or treat illnesses caused by O157. The invention further relates to the antibodies which immunoreact with the O-specific polysaccharide of O157 and/or the carrier, that are induced by these conjugates and/or compositions thereof. The invention also relates to methods and kits using one or more of the polysaccharides, conjugates or antibodies described above.

US Patent:

7422755, Sep 9, 2008

Filed:

Jan 18, 2005

Appl. No.:

11/035884

Inventors:

Rachel Schneerson - Bethesda MD, US
John B. Robbins - Chevy Chase MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 45/00
A61K 39/00
C12P 19/00
C07K 1/00
C07K 16/00

US Classification:

4242781, 435 72, 4241841, 530350, 5303881

Abstract:

The present invention relates, e. g. , to a glycoconjugate composition comprising one or more polysaccharide types from a cell wall polysaccharide preparation from Sh 18, or variants thereof. Also disclosed are antibodies generated against the glycoconjugates, and methods of using the glycoconjugates and antibodies. An antimultiorganism vaccine which reacts against at least type a, type b, , and , is disclosed.

US Patent:

7527797, May 5, 2009

Filed:

Sep 1, 2000

Appl. No.:

10/363618

Inventors:

Shousun Chen Szu - Bethesda MD, US
Zuzana Kossaczka - Bethesda MD, US
John B. Robbins - Chevy Chase MD, US

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/00
A61K 39/38
A61K 39/40
A61K 39/385
A61K 39/116
A61K 39/02
A61K 39/106
A61K 38/00
A61K 38/16
A01N 37/18
C12P 21/08
C08H 1/00
C07K 16/00

US Classification:

4241931, 4241841, 4242611, 4241641, 4241941, 4242341, 4242031, 4242361, 4241791, 4242001, 4241831, 5303871, 5303891, 530403, 514 2, 514 8

Abstract:

The invention pertains to conjugates of the capsular polysaccharide of O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against , in particular O139, and are useful to prevent, treat and/or reduce the severity of disease caused by infection, such as cholera. The present invention also relates to diagnostic tests for infection, and/or cholera caused by infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.